末端Galβ1-4GlcNAc多糖分子在肿瘤患者血清中的表达

Investigation of Expression of the Terminal Galbeta1-4GlcNAc Related Polysaccharide in Serum of Malignant Tumors Patients

目的研究末端Galβ1-4GlcNAc多糖分子在鼻咽癌、肺癌、肝癌和结直肠癌患者血清中的表达规律。方法应用RCAⅠ(蓖麻凝集素Ⅰ)亲和层析法从正常人血清中获得RCAⅠ相关末端Galβ1-4GlcNAc糖蛋白,用辣根过氧化物酶标记,采用凝集素差减法,对133例肿瘤患者,64例良性疾病患者和240例正常人血清进行检测。结果鼻咽癌、肝癌和结直肠癌患者血清中RCAⅠ识别的多糖分子明显高于正常人和良性疾病患者,阳性率分别为66.7%、73.9%、64.9%;肺癌患者血清阳性率为19.4%。且在鼻咽癌和结直肠癌患者有效治疗后该多糖分子水平显著下降,阳性率也下降。结论血清中RCAⅠ相关的末端Galβ1-4GlcNAc多糖分子,可用于肿瘤患者血清糖基化异常和肿瘤发病机制的研究,并可为临床诊断和治疗效果的评价提供参考指标。

Objective To detect the expression of the terminal Galbetal-4GlcNAc related polysaccharide in serum of nasopharyngeal carcinoma, primary liver cancer, and colorectal cancer and lung cancer patients. Methods The RCA Ⅰ identifying Terminal Galβ1-4 GlcNAc glycoprotein was acquired by RCA Ⅰ （Ricinus communis agglutinin Ⅰ ） affinity chromatography method from norreal person serum and was marked by the horseradish peroxidase. 133 tumor patients,64 benign disease patients and 240 normal person serums were detected by the subtraction of agglutinin. Results The polysaccharide level of the RCA Ⅰ identification in serum of nasopharyngeal carcinoma, primary liver cancer and colorectal cancer was obvious higher than it in normal person and benign disease patients. The positive rate was 66. 7% ,73. 9% and 64. 9% relatively. Lung cancer had only positive rate 19. 4%. After effective therapy, the polysaccharide lever of the RCA Ⅰ identification in serum of nasopharyngeal carcinoma and colorectal cancer remarkably descent, the positive rate also descent. Conclusion The terminal Galbetal-4GlcNAc related polysac- haride in serum can be applied to the research of abnormal polysaccharide in tumor patient and pathogenesis. Its level can provide reference for clinical diagnosis and the evaluation on curative effect.